7 results about "Skin atrophy" patented technology

The invention discloses a stem cell exosome composition as well as a preparation method and application thereof. The stem cell exosome composition is prepared from the following raw materials in parts by weight: 0.0000168 to 0.00004 part of umbilical cord mesenchymal stem cell exosome, 0.8 to 1.2 parts of polydeoxyribonucleotide, 1.44 to 2.16 parts of III type collagen, 0.31 to 0.48 part of sodium hyaluronate and 50 to 150 parts of normal saline. According to the application, the bioavailability and repairing efficiency of active ingredients in a corium layer can be remarkably improved, and the application has the advantage of remarkable effect on repairing intractable skin barrier damage, refractory sensitive skin and severe skin atrophy and elasticity loss caused by aging.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

This invention relates to the field of biomedical technology, and more particularly to the application of XPO1 inhibitors in the preparation of drugs for the topical treatment of pruritus. Experimental studies have shown that XPO1 inhibitors have significant therapeutic effects on chronic and complex pruritus models, and may be applicable to pruritus caused by various etiologies, possessing broad-spectrum therapeutic potential. By administering the drug topically, it primarily acts on the local skin, greatly avoiding the serious systemic side effects (such as hematological toxicity and gastrointestinal reactions) associated with oral XPO1 inhibitors. Simultaneously, it also avoids the local side effects such as skin atrophy caused by long-term use of potent hormones. This invention provides a novel drug option for the treatment of intractable pruritus and related inflammatory skin diseases.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an application of coptis chinensis paste in preparation of a medicine for treating or preventing atopic dermatitis, and the coptis chinensis paste is used for treating the atopic dermatitis by repairing a skin barrier and regulating immune response. Pharmacodynamic verification proves that the rhizoma coptidis paste shows a good curative effect in the aspect of improving AD-like dermatitis symptoms, skin atrophy side effects similar to dexamethasone are not observed at a high dosage, and the rhizoma coptidis paste shows better treatment safety characteristics. According to the application disclosed by the invention, the action mechanism of the coptis chinensis cream for treating atopic dermatitis is defined, the coptis chinensis cream promotes synthesis of skin barrier structural protein to consolidate defense and effectively inhibits release of alarm elements such as TSLP / IL-33 to block inflammation initiation, finally, effector factors such as IL-4 / IL-13 and the like and IgE are reduced, inflammatory cell reactions such as mastocyte infiltration are relieved, and the curative effect of the coptis chinensis cream on atopic dermatitis is improved. Therefore, clinical symptoms and pathological changes of AD are improved.

The invention relates to a triamcinolone acetonide and econazole cream for promoting barrier repair and a preparation method of the triamcinolone acetonide and econazole cream. According to the triamcinolone acetonide and econazole cream, the brown algae extract rich in fucosan is creatively introduced, so that the triamcinolone acetonide and econazole cream keeps the original anti-inflammatory and anti-fungal curative effects, meanwhile, the risks of local adverse reactions such as skin atrophy and angiotelectasis caused by triamcinolone acetonide are effectively relieved, generation of fungal drug resistance is inhibited, and the triamcinolone acetonide and econazole cream has a good application prospect. The barrier repairing and moisturizing capabilities of the skin are obviously enhanced. Besides, the red algae extract is introduced into the cream formula, and the red algae extract and the brown algae extract play a synergistic effect, so that local adverse reactions are further relieved, fungal drug resistance is inhibited, and the barrier repairing and moisturizing capacity of the skin is enhanced.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.